Lonza to buy Genentech’s biologics manufacturing site in California for $1.2bn
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Mar 24
The deal is anticipated to boost Lonza's large-scale biologics manufacturing capacity and will also help the firm cope…
06 Feb 24
Novo Nordisk has agreed to acquire Catalent’s three fill-finish sites located in Anagni, Italy; Brussels, Belgium; and Bloomington,…
14 Nov 23
The acquisition of Forge Biologics is expected to expand Ajinomoto’s AAV and plasmid gene therapy manufacturing capabilities, while…
24 Oct 23
As per the multi-year agreement, Samsung Biologics will offer Kurma Partners' portfolio companies with customised services for chemistry,…
27 Sep 23
The DP facility is equipped with an automatic vial washing, sterilizing, filling and capping line, which can support…
10 Aug 23
As part of the expansion of the Milan site, AGC Biologics has added five suspension single-use bioreactors, including…
07 Jun 23
Scheduled to open in July 2023, the new regional commercial office located in Minato, Tokyo, will be part…
05 May 23
Under the terms of the agreement, Novocol Pharma will provide fill-finish and packaging for vaccines manufactured at Moderna’s…
20 Mar 23
The contract development and manufacturing organisation (CDMO) intends to build Plant 5 at Bio Campus II, with a…
15 Mar 23
The Rockford hub will have product testing capability, top-load cartoning technology, and injector and pen assembly equipment